Cargando…

Effect of Acarbose on Long-Term Prognosis in Acute Coronary Syndromes Patients with Newly Diagnosed Impaired Glucose Tolerance

Objective. To investigate the effect of acarbose therapy on the long-term prognosis of patients with acute coronary syndromes (ACS) complicating newly diagnosed impaired glucose tolerance (IGT). Methodology. 135 patients hospitalized for ACS who had been newly diagnosed with IGT were randomly assign...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yun, Peng, Du, Ai-ming, Chen, Xue-jun, Liu, Jing-cheng, Xiao, Hu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2016
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4684859/ https://www.ncbi.nlm.nih.gov/pubmed/26770983 http://dx.doi.org/10.1155/2016/1602083

Ejemplares similares

Assessment of Insulin Resistance in Subjects with Normal Glucose Tolerance, Hyperinsulinemia with Normal Blood Glucose Tolerance, Impaired Glucose Tolerance, and Newly Diagnosed Type 2 Diabetes (Prediabetes Insulin Resistance Research)
por: Yang, Guang, et al.
Publicado: (2016)

Predictors of acarbose therapeutic efficacy in newly diagnosed type 2 diabetes mellitus patients in China
por: Zhang, Rong, et al.
Publicado: (2022)

Impaired Glucose Tolerance or Newly Diagnosed Diabetes Mellitus Diagnosed during Admission Adversely Affects Prognosis after Myocardial Infarction: An Observational Study
por: George, Anish, et al.
Publicado: (2015)

The Effects of Gliclazide, Metformin, and Acarbose on Body Composition in Patients with Newly Diagnosed Type 2 Diabetes Mellitus()
por: Wang, Hua, et al.
Publicado: (2013)

Effect of acarbose combined with diet intervention on glycolipid metabolism in patients with primary polycystic ovarian syndrome complicated with impaired glucose tolerance
por: Yang, Qian, et al.
Publicado: (2022)

Factors associated with improvement in waist-to-height ratio among newly diagnosed type 2 diabetes patients treated with acarbose or metformin: A randomized clinical trial study
por: Song, Lu-Lu, et al.
Publicado: (2020)

MARCH2: Comparative Assessment of Therapeutic Effects of Acarbose and Metformin in Newly Diagnosed Type 2 Diabetes Patients
por: Wang, Guang, et al.
Publicado: (2014)

MARCH: factors associated with weight loss in patients with newly diagnosed type 2 diabetes treated with acarbose or metformin
por: Wang, Na, et al.
Publicado: (2018)

Acarbose Reduces Low-Grade Albuminuria Compared to Metformin in Chinese Patients with Newly Diagnosed Type 2 Diabetes
por: Song, Lulu, et al.
Publicado: (2021)

Effects of a novel combination of orlistat and acarbose on tolerability, appetite, and glucose metabolism in persons with obesity
por: Holmbäck, Ulf, et al.
Publicado: (2020)

Influence of Acarbose on Plasma Glucose Fluctuations in Insulin-Treated Patients with Type 2 Diabetes: A Pilot Study
por: Li, Feng-fei, et al.
Publicado: (2015)

Comparison of Acarbose and Metformin on Albumin Excretion in Patients With Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial
por: Pan, Qingrong, et al.
Publicado: (2016)

Metformin or Acarbose Treatment Significantly Reduced Albuminuria in Patients with Newly Diagnosed Type 2 Diabetes Mellitus and Low-Grade Albuminuria
por: Pan, Qingrong, et al.
Publicado: (2018)

Single-dose acarbose decreased glucose-dependent insulinotropic peptide and glucagon levels in Chinese patients with newly diagnosed type 2 diabetes mellitus after a mixed meal
por: Chen, Zhong, et al.
Publicado: (2016)

The Beta-Cell Function and Glucose Profile of Newly Diagnosed Acromegalic Patients with Normal Glucose Tolerance
por: Sun, Quanya, et al.
Publicado: (2021)

Effects of acarbose and metformin on the inflammatory state in newly diagnosed type 2 diabetes patients: a one-year randomized clinical study
por: Mo, Dan, et al.
Publicado: (2019)

Impaired secretion of glucagon-like peptide 1 during oral glucose tolerance test in patients with newly diagnosed type 2 diabetes mellitus
por: Wang, Xiao-Li, et al.
Publicado: (2016)

Serum homocysteine level in newly diagnosed young patients with abnormal glucose tolerance
por: Rijal, Amrit, et al.
Publicado: (2023)

Acarbose is again on the stage
por: Altay, Mustafa
Publicado: (2022)

Effects of 24-week treatment with acarbose on glucagon-like peptide 1 in newly diagnosed type 2 diabetic patients: a preliminary report
por: Zheng, Miao-yan, et al.
Publicado: (2013)

Long-term prognosis in patients with acute myocardial infarction and newly detected glucose abnormalities: predictive value of oral glucose tolerance test and HbA1c
por: Karayiannides, Stelios, et al.
Publicado: (2021)

The effects of acarbose treatment on cardiovascular risk factors in impaired glucose tolerance and diabetic patients: a systematic review and dose–response meta-analysis of randomized clinical trials
por: Zamani, Mohammad, et al.
Publicado: (2023)

Impaired β Cell Function in Chinese Newly Diagnosed Type 2 Diabetes Mellitus with Hyperlipidemia
por: Ma, Yuhang, et al.
Publicado: (2014)

Comparison of Efficacy and Safety of Lispro and Aspart Evaluated by Continuous Glucose Monitoring System in Patients with Newly Diagnosed Type 2 Diabetes
por: Liu, Bing-li, et al.
Publicado: (2018)

Continuous Glucose Monitoring in Newly Diagnosed Type 2 Diabetes Patients Reveals a Potential Risk of Hypoglycemia in Older Men
por: Li, Feng-fei, et al.
Publicado: (2017)

Impact of newly diagnosed abnormal glucose regulation on long-term prognosis in low risk patients with ST-elevation myocardial infarction: A follow-up study
por: Knudsen, Eva C, et al.
Publicado: (2011)

Exploration of suitable pharmacodynamic parameters for acarbose bioequivalence evaluation: A series of clinical trials with branded acarbose
por: Huang, Jie, et al.
Publicado: (2020)

Acarbose for Postprandial Hypotension With Glucose Metabolism Disorders: A Systematic Review and Meta-Analysis
por: Wang, Biqing, et al.
Publicado: (2021)

Interstitial photodynamic therapy for newly diagnosed glioblastoma
por: Quach, Stefanie, et al.
Publicado: (2023)

On the potential of acarbose to reduce cardiovascular disease
por: Standl, Eberhard, et al.
Publicado: (2014)

Plaque Characteristics in Coronary Artery Disease Patients with Impaired Glucose Tolerance
por: Suzuki, Keishi, et al.
Publicado: (2016)

Long-term morbidity and mortality in patients diagnosed with an insulinoma
por: Peltola, Elina, et al.
Publicado: (2021)

Newly diagnosed glucose intolerance and prognosis after acute myocardial infarction: comparison of post-challenge versus fasting glucose concentrations
por: Tamita, Koichi, et al.
Publicado: (2012)

Identical anthropometric characteristics of impaired fasting glucose combined with impaired glucose tolerance and newly diagnosed type 2 diabetes: anthropometric indicators to predict hyperglycaemia in a community-based prospective cohort study in southwest China
por: Zhang, Fang, et al.
Publicado: (2018)

Combined use of basal insulin analog and acarbose reduces postprandial glucose in patients with uncontrolled type 2 diabetes
por: Kim, Ji-Hyun, et al.
Publicado: (2015)

Evaluation of the pharmacokinetics of metformin and acarbose in the common marmoset
por: Fernandez, Elizabeth, et al.
Publicado: (2019)

Acarbose improved survival for Apc(+/Min) mice
por: Dodds, Sherry G., et al.
Publicado: (2020)

Evaluation of the Bioequivalence of Acarbose in Healthy Chinese People
por: Chen, Yan, et al.
Publicado: (2021)

Complete biosynthetic pathway to the antidiabetic drug acarbose
por: Tsunoda, Takeshi, et al.
Publicado: (2022)

Diagnosing Impaired Glucose Tolerance Using Direct Infusion Mass Spectrometry of Blood Plasma
por: Lokhov, Petr G., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_dc8cet4lsjkmst2nergf8d5k5i